 |
National HIV/AIDS Program |  | | |
| HIV Meds Quarterly| HIV Meds Quarterly provides brief updates and analysis of new findings related to common therapies used by HIV clinicians. |
 | | | - Research Briefs: Pregabalin for Neuropathic Pain: Not More Effective Than Placebo; Abacavir/Lamivudine: Higher Rates of Virologic Failure in ARV-Naive Patients with HIV RNA ≥100,000 copies/mL compared with Tenofovir/Emtricitabine; Abacavir and Risk of Myocardial Infarction: The SMART Study
- Interactions: Atazanavir: Interactions with Efavirenz, Nevirapine, and Oral Hormonal Contraceptives
- Fast Takes: Recent news about ritonavir, darunavir, atazanavir + ritonavir, tenofovir, zidovudine, and didanosine
|
| | | - Research Briefs: Abacavir and Didanosine Associated with Increased Risk of Myocardial Infarction; Testing for Chemokine Coreceptor Tropism
- Interactions: Rosuvastatin with Lopinavir/Ritonavir and Tipranavir; Rifampin and "Super-Boosted" Protease Inhibitors
- Fast Takes: Recent news about nelfinavir, tipranavir, lopinavir/ritonavir, and nevirapine
|
| | | - Research Briefs: Atazanavir Efficacy Data and Changes in Dosage Recommendations; Raltegravir Substitution for Enfuvirtide; HLA-B*5701 Screening
- Reference Table: Etravirine-ARV Interactions
- Fast Takes: Recent news about darunavir, lamivudine, lopinavir/ritonavir and amprenavir
|
| | | |
|
| | |
|
| Reviewed/Updated Date: October 30, 2008 |
|
